Biotech - Press Releases

Date	Title	Company
13-Feb-2020	Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™	Abeona Therapeutics Inc.
13-Feb-2020	Sosei Heptares Operational HighlightsSosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2019 and Consolidated Results for the 12 Months ended 31 December 2019	Sosei Heptares
13-Feb-2020	First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis	Sanifit
13-Feb-2020	The Alliance for Regenerative Medicine Releases Agenda for 2020 Cell & Gene Meeting on the Mediterranean	Alliance for Regenerative Medicine
13-Feb-2020	New gene mutation associated with Fabry cardiomyopathy	University of Eastern Finland
13-Feb-2020	SCTM roadmap and committed funding will boost Australia’s position in Asia-Pacific stem cell research landscape, says GlobalData	GlobalData
13-Feb-2020	New genetic sequencing platform sheds more light on how a household antibacterial kills bacteria	Quadram Institute and University of East Anglia
13-Feb-2020	Improvements welcome but NHS 'not out of the woods', says NHS Confederation	NHS
13-Feb-2020	XBiotech Announces Preliminary Results of Tender Offer	XBiotech Inc
13-Feb-2020	Science 37® Enhances Its Patient Experience and Introduces Native Support for iOS and Android	Science 37
13-Feb-2020	OptionTrax® Launches Instant, Flexible E-Stock Certificates	OptionTrax
13-Feb-2020	Q BioMed Launches Non-opioid Treatment for Metastatic Bone Pain	Q BioMed Inc.
13-Feb-2020	Creative Medical Technology Holdings, Inc. February 2020 Shareholder Update	Creative Medical Technology Holdings, Inc.
13-Feb-2020	SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)	SCYNEXIS, Inc.
13-Feb-2020	Thermo Fisher Scientific Announces Collaboration to Develop Highly Sensitive Analytical Workflow for Infectious Disease Diagnosis and Patient Monitoring	Thermo Fisher Scientific
13-Feb-2020	Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients	Trovagene, Inc.
13-Feb-2020	Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.	Armata Pharmaceuticals, Inc.
13-Feb-2020	Domainex announces the appointment of Tom Mander as Chief Executive Officer	Domainex Ltd
13-Feb-2020	Sobi Publishes Report for the Fourth Quarter and Full-year 2019	Swedish Orphan Biovitrum AB
12-Feb-2020	Akorn Announces New Extension of Standstill with Lenders and Agrees to Pursue a Sale of its Business	Akorn, Inc.